ADOCIA Announces that it has Received €500.000 in Proceeds from a Partial Exercise of Warrants Held by IPF Partners
31 Agosto 2023 - 11:00AM
Business Wire
Regulatory News:
Adocia (Euronext Paris : FR0011184241 – ADOC), a
clinical-stage biopharmaceutical company specializing in the
development of innovative formulations of proteins and peptides for
the treatment of diabetes and other metabolic diseases (the
“Company”), announced today that IPF Partners ("IPF")
has exercised part of its warrants (bons de souscription d’actions
or "Warrants"), resulting in the issue of 204,919 shares at
a price of €2.44 euros per share, for a total subscription price of
approximately €500,000.
The Warrants that were issued to IPF in 2019 concomitantly to
the execution of the first loan agreement, then in 2020 when the
Company's debt was restructured, give the right to subscribe for a
number of Company’s ordinary shares equal to 15% of the loan, i.e.,
€2,550,000 in total, divided by a price per share equal to 95% of
the lowest subscription price of any ordinary share issued by the
Company during the exercise period of the Warrants (as further
described in chapter 1.2.6.6 of the Company's 2022 Universal
Registration Document), i.e. currently €2.44, corresponding to 95%
of the issue price of the shares issued on conversion of bonds by
Vester Finance in April 2023.
On this basis, the balance of the Warrants held by IPF Partners
(after the aforementioned exercise of part of the Warrants), which
may be exercised until October 2026, currently entitles holders to
subscribe to 840,162 shares in return for a total payment to the
Company of around €2,050,000.
The admission to trading of the shares to which the Warrants
give right will be the subject of a listing prospectus submitted to
the AMF for approval in the coming weeks.
About Adocia
Adocia is a biotechnology company specializing in the discovery
and development of therapeutic solutions in the field of metabolic
diseases, primarily diabetes and obesity.
The company has a broad portfolio of drug candidates based on
four proprietary technology platforms: 1) The BioChaperone®
technology for the development of new generation insulins and
products combining insulins with other classes of hormones; 2)
AdOral®, an oral peptide delivery technology; 3) AdoShell®, an
immunoprotective biomaterial for cell transplantation, with a first
application in pancreatic cells transplantation; 4) AdoGel®, a
long-acting drug delivery platform.
Adocia holds more than 25 patent families. Based in Lyon, the
company has about 100 employees. Adocia is listed on the regulated
market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).
Disclaimer
This press release contains certain forward-looking statements
concerning Adocia and its business. Such forward-looking statements
are based on assumptions that Adocia considers as being reasonable.
However, there can be no guarantee that the estimates contained in
such forward-looking statements will be achieved, as such estimates
are subject to numerous risks including those which are set forth
in the “Risk Factors” section of the universal registration
document that was filed with the French Autorité des marchés
financiers on April 26, 2023 updated by the amendment of 26 July
2023 (D.23-0346-A01) available at www.adocia.com, in particular
uncertainties that are linked to research and development, future
clinical data, analyses, and the evolution of the economic context,
the financial markets and the markets in which Adocia operates.
The forward-looking statements contained in this press release
are also subject to risks not yet known to Adocia or not considered
as material by Adocia as of this day. The occurrence of all or part
of such risks could cause that actual results, financial
conditions, performances, or achievements of Adocia be materially
different from those mentioned in the forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230831170908/en/
Adocia Olivier Soula CEO
contactinvestisseurs@adocia.com +33 (0)4 72 610 610
www.adocia.com
Ulysse Communication Adocia Relations Presse et
Investisseurs Pierre-Louis Germain Bruno Arabian
adocia@ulysse-communication.com + 33 (0)6 64 79 97 51
Edoc Acquisition (NASDAQ:ADOC)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Edoc Acquisition (NASDAQ:ADOC)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024